EN
  • FR
Contact
  • News
  • Media
  • Health professionals
  • CAREERS
LFB corp
  • The group
    • The LFB group
    • LFB Key dates
    • LFB worldwide
    • A special place in France
    • Governance
      • LFB SA Board of Directors
      • Group Executive Committee
      • LFB BIOMEDICAMENTS
      • LFB BIOTECHNOLOGIES
      • Composition and tasks of the Committees
  • Products and activities
    • Medicinal products
    • Biosafety
    • LFB Research Grant in Immunology
    • The Powers of Blood
  • Innovation
    • Products under development
    • Technology platforms
    • Improving biosafety
  • Responsibilities
    • Rare diseases
    • Relations with patients’ associations
    • A responsible company
    • Transparency of interests for France
  • The LFB group

    LFB is a pharmaceutical group specialising in plasma derived or recombinant therapeutic proteins for the treatment of serious and often rare diseases.

  • LFB Key dates

    Since the creation of LFB in January 1994, discover the dates that gone down the Group's history.

  • LFB worldwide

    Worldwide, LFB has decided on a targeted strategy

  • A special place in France

    LFB has a special place in France, as a player in the healthcare industry with a public health mission

  • Governance

    A public company active in a competitive market

  • Medicinal products

    15 hospital-prescribed medicinal products

  • Biosafety

    Patient safety, a top priority for LFB

  • LFB Research Grant in Immunology

    LFB commits to research in the field of immunology every year.

  • The Powers of Blood

    Our series of 5 educational videos

  • Products under development

    There are several medicinal products at an advanced stage of development, for registration in Europe and the USA

  • Technology platforms

    Two proprietary platforms for therapeutic and technological innovation

  • Improving biosafety

    Innovations to constantly improve the biosafety of medicinal products

  • Rare diseases

    LFB has a continuing commitment to social issues, offering several therapeutic solutions, both currently on sale and under development, for rare diseases

  • Relations with patients’ associations

    LFB is a partner in several patients’ associations and supports projects focused on a better quality of life for patients and their families

  • A responsible company

    LFB’s ethical commitment is reflected in the way it exercises its environmental, social and economic responsibilities

  • Transparency of interests for France

    Transparency of interests for France

Medicinal products
marketed in
40 countries

burger

Home › The group › Governance

A limited company with predominantly
public share capital

The LFB Group, a French biopharmaceutical company, is a limited company
with predominantly public share capital, the French State
now being the sole shareholder.

Group Executive Committee

The LFB Group Executive Committee is chaired by Jacques Brom, CEO of LFB.

Read more

LFB SA Board of Directors

Composition of the LFB SA Board of Directors, chaired by Corinne Fau, Member of the Board and Chief Financial Officer for Enedis.

Read more

LFB BIOMEDICAMENTS

LFB BIOMEDICAMENTS, a subsidiary of LFB SA, specialises in plasma-derived medicinal products, is headed by Jacques Brom.

Read more

LFB BIOTECHNOLOGIES

LFB BIOTECHNOLOGIES, a wholly-owned subsidiary of LFB SA, has its head office in Les Ulis (France).

Read more

Composition and tasks of the Committees

Composition and tasks of the Audit and Compensation committee and the strategy committee

Read more

Follow us on

  • The group
    • The LFB group
    • LFB Key dates
    • LFB worldwide
    • A special place in France
      • A player in the healthcare industry
      • A public health mission in france
    • Governance
      • Group Executive Committee
      • LFB BIOMEDICAMENTS
      • LFB BIOTECHNOLOGIES
      • Composition and tasks of the Committees
  • The Powers of Blood
  • Products and activities
    • Medicinal products
      • Immunology
      • Haemostasis
      • Intensive care
    • LFB Research Grant in Immunology
    • The Powers of Blood
    • Biosafety
  • Innovation
    • Products under development
    • Technology platforms
      • EMABling®
      • rPRO™ technology
    • Improving biosafety
  • Responsibilities
    • Rare diseases
    • Relations with patients’ associations
    • A responsible company
      • Environmental responsibility
      • Social responsibility
      • Economic responsibility
    • Transparency of interests for France
  • Site map
  • Legal notices
  • Processing of personal data
  • Cookie management policy
  • Cookies management panel
  • Adverse effect reporting
 
 
 

 

×